Therefore, we assessed the effect of Sorafenib, another SLC7A11-targeting ferroptosis inducer that has been used for liver cancer therapy in clinic, on Tamoxifen resistant ZR-75-1 cells in vitro and in vivo. The gene discussed is SLC7A11; the disease is liver cancer.